DDInter222 DDInter1826
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic
A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Tolazamide
Bortezomib {u} (Compound) upregulates {v} (Gene) TSC22D3
TSC22D3 {u} (Gene) is upregulated by {v} (Compound) Tolazamide
Bortezomib {u} (Compound) downregulates {v} (Gene) JADE2
JADE2 {u} (Gene) is upregulated by {v} (Compound) Tolazamide
Bortezomib {u} (Compound) upregulates {v} (Gene) IER3
IER3 {u} (Gene) is downregulated by {v} (Compound) Tolazamide
Bortezomib {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) PSMD2
PSMD2 {u} (Gene) is downregulated by {v} (Compound) Tolazamide
Bortezomib {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Tolazamide
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Sulfacetamide
Sulfacetamide {u} (Compound) resembles {v} (Compound) Tolazamide
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Tolazamide
Bortezomib {u} (Compound) downregulates {v} (Gene) JADE2
JADE2 {u} (Gene) is upregulated by {v} (Compound) Glyburide
Glyburide {u} (Compound) resembles {v} (Compound) Tolazamide
Bortezomib {u} (Compound) upregulates {v} (Gene) IER3
IER3 {u} (Gene) regulates {v} (Gene) PSMD2
PSMD2 {u} (Gene) is downregulated by {v} (Compound) Tolazamide
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Tolazamide (Compound)
Bortezomib (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Tolazamide (Compound)
Bortezomib (Compound) downregulates JADE2 (Gene) and JADE2 (Gene) is upregulated by Tolazamide (Compound)
Bortezomib (Compound) upregulates IER3 (Gene) and IER3 (Gene) is downregulated by Tolazamide (Compound)
Bortezomib (Compound) binds PSMD2 (Gene) and Bortezomib (Compound) upregulates PSMD2 (Gene) and PSMD2 (Gene) is downregulated by Tolazamide (Compound)
Bortezomib (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Tolazamide (Compound)
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide (Compound) resembles Tolazamide (Compound)
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound) and Tolbutamide (Compound) resembles Tolazamide (Compound)
Bortezomib (Compound) downregulates JADE2 (Gene) and JADE2 (Gene) is upregulated by Glyburide (Compound) and Glyburide (Compound) resembles Tolazamide (Compound)
Bortezomib (Compound) upregulates IER3 (Gene) and IER3 (Gene) regulates PSMD2 (Gene) and PSMD2 (Gene) is downregulated by Tolazamide (Compound)